Cornerstone Pharmaceuticals Lead Compound CPI-613
Selectively Targeting Metabolism in Mitochondria In Cancer Cells | Cancer Biology
Prolongation of survival induced by four doses of CPI-613 (25 mg/kg),... | Download Scientific Diagram
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process | SpringerLink
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
ラファエルホールディングスの適時開示・その他 | 米国株｜株探（かぶたん) - 株探
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. - Abstract - Europe PMC
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? | Oncotarget
Devimistat | CPI-613 | CAS#95809-78-2 | Antineoplastic | MedKoo Biosciences
Rafael Holdings, Inc. 2021 Current Report 8-K
An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio) - ScienceDirect
A combination of CPI-613 and chloroquine significantly suppressed tumor... | Download Scientific Diagram
Finding Targets in Cancer's Metabolic Quirks
Devimistat – Drug Approvals International
Mitochondria in cancer metabolism, an organelle whose time has come? - Abstract - Europe PMC
Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog | medRxiv
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial - The Lancet Oncology
Devimistat (CPI-613) (Devimistat) | CAS 95809-78-2 | AbMole BioScience | Devimistat (CPI-613) Price
CPI-613 (Devimistat) | ≥99%(HPLC) | Dehydrogenase Inhibitor | AdooQ®
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
Devimistat - Wikipedia
